• October 5, 2020

    Patients with rheumatic disease are less likely to suffer from coronavirus, especially those taking hydroxychloroquine. That is why their therapy should not be interrupted during the pandemic, says rheumatologist Prof. Rasho Rashkov and clarifies that he and his colleagues have many years of experience in the treatment with hydroxychloroquine, as well as treatment of some of the complications caused by the infection.

    The full article is available here in Bulgarian.

  • October 3, 2020

    Tchaikapharma High Quality Medicines Inc. remains the most expensive Bulgarian company on the Bulgarian Stock Exchange. After the market capitalization of the pharmaceutical company exceeded BGN 1 billion at the end of June, in July, August and September it added more value to its stock market valuation.

    The full article is available here in Bulgarian.

  • July 13, 2020

    There is a company on the Bulgarian Stock Exchange with a value of over a billion leva, according to data in the bulletin of the stock exchange operator for the second quarter. This is Tchaikapharma High Quality Medicines. By the end of June, the stock exchange players estimated the pharmaceutical company at BGN 1,027,500,000.


    Read the full article here in Bulgarian.

  • July 7, 2020

    Briefing at the Ministry of health

  • June 30, 2020

    Global COVID-19 prevention trial of hydroxychloroquine to resume


    LONDON (Reuters) – A global trial designed to test whether the anti-malaria drugs hydroxychloroquine and chloroquine can prevent infection with COVID-19 is to restart after being approved by British regulators.


    The Medicines and Healthcare Products Regulatory Agency (MHRA) took its decision on what is known as the COPCOV trial after hydroxychloroquine was found in another British trial to have no benefit as a treatment for patients already infected with COVID-19, the disease caused by the new coronavirus.


    The COPCOV study was paused pending review after the treatment trial results.


    It is a randomised, placebo-controlled trial that is aiming to enrol 40,000 healthcare workers and other at-risk staff around the world, and is being led by the Oxford University’s Mahidol Oxford Tropical Medicine Research Unit (MORU) in the Thai capital, Bangkok.


    U.S. President Donald Trump said in March hydroxychloroquine could be a game-changer and then said he was taking it himself, even after the U.S. regulator, the Food and Drug Administration (FDA), advised that its efficacy and safety were unproven.


    The FDA later revoked emergency use authorisation for the drugs to treat COVID-19, after trials showed they were of no benefit as treatments.


    But Oxford University’s Professor Nicholas White, who is co-leading the COPCOV trial, said studies of the drugs as a potential preventative medicine had not yet given a conclusive answer.


    “Hydroxychloroquine could still prevent infections, and this needs to be determined in a randomised controlled trial,” he said in a statement. “The question whether (it) can prevent COVID-19 or not remains as pertinent as ever.”


    White’s team said recruitment of British health workers would resume this week, and said plans were under way for new sites in Thailand and Southeast Asia, Africa and South America. Results are expected by the end of this year.


    The death toll from COVID-19 surpassed half a million people on Sunday, according to a Reuters tally, with the number of cases reported globally now more than 10 million.



    Source: Reuters


    More information: Vimeo